A Phase I Study of MSB2311 in Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity,
biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D)
in subjects with advanced solid tumors.